Cladribine Patent Expiration

Cladribine is used for treating multiple sclerosis (MS) with oral cladribine. It was first introduced by Janssen Pharmaceuticals Inc in its drug Leustatin on Feb 26, 1993. Another drug containing Cladribine is Mavenclad. 6 different companies have introduced drugs containing Cladribine.


Cladribine Patents

Given below is the list of patents protecting Cladribine, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Mavenclad US10849919 Cladribine regimen for treating progressive forms of multiple sclerosis Nov 23, 2038 Emd Serono Inc
Mavenclad US7713947 Cladribine regimen for treating multiple sclerosis Oct 16, 2026 Emd Serono Inc
Mavenclad US8377903 Cladribine regimen for treating multiple sclerosis May 31, 2026 Emd Serono Inc
Mavenclad US7888328 Oral formulations of cladribine Apr 11, 2024

(Expired)

Emd Serono Inc
Mavenclad US8785415 Oral formulations of cladribine Apr 11, 2024

(Expired)

Emd Serono Inc



Cladribine's Family Patents

Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List

Cladribine Generic API Manufacturers

Several generic applications have been filed for Cladribine. The first generic version for Cladribine was by Hikma Pharmaceuticals Usa Inc and was approved on Feb 28, 2000. And the latest generic version is by Hisun Pharmaceutical (Hangzhou) Co Ltd and was approved on Nov 25, 2019.

Given below is the list of companies who have filed for Cladribine generic, along with the locations of their manufacturing plants worldwide.


1. FRESENIUS KABI USA

Fresenius Kabi Usa Llc has filed for 1 generic for Cladribine. Given below are the details of the strengths of this generic introduced by Fresenius Kabi Usa.

Strength Dosage Form Availability Application Pathway TE code Launch Date
1MG/ML

(reference standard)

injectable Prescription INJECTION AP Apr 22, 2004


Manufacturing Plant Locations
New

Fresenius Kabi Usa's manufacturing plants are situated in 1 country - United States. Given below are the details of these plant locations as well as the firm names of Fresenius Kabi Usa as present at those locations.

Country City Firm Name
United States
Melrose Park Fresenius Kabi USA, LLC
Wilson Fresenius Kabi USA, LLC
Skokie Fresenius Kabi USA LLC
Grand Island Fresenius Kabi USA, LLC
North Andover Fresenius Kabi USA, LLC
Bensenville Fresenius Kabi USA LLC (FK USA)
Melrose Park Fresenius Kabi USA LLC
Lake Zurich Fresenius Kabi USA, LLC





2. HIKMA

Hikma Pharmaceuticals Usa Inc has filed for 1 generic for Cladribine. Given below are the details of the strengths of this generic introduced by Hikma.

Strength Dosage Form Availability Application Pathway TE code Launch Date
1MG/ML

injectable Prescription INJECTION AP Feb 28, 2000


Manufacturing Plant Locations
New

Hikma's manufacturing plants are situated in 3 countries - United States, Portugal, Jordan. Given below are the details of these plant locations as well as the firm names of Hikma as present at those locations.

Country City Firm Name
United States
Eatontown Hikma Pharmaceuticals USA, Inc.
Cherry Hill Hikma Pharmaceuticals USA Inc.
Dayton Hikma Injectables USA Inc
Carlsbad Hikma Cali Inc. DBA Leucadia Pharmaceuticals
Portugal
Terrugem Snt Hikma Farmaceutica, (Portugal) S.A.
Jordan
Amman Hikma Pharmaceuticals LLC





3. HISUN PHARM HANGZHOU

Hisun Pharmaceutical (hangzhou) Co Ltd has filed for 1 generic for Cladribine. Given below are the details of the strengths of this generic introduced by Hisun Pharm Hangzhou.

Strength Dosage Form Availability Application Pathway TE code Launch Date
1MG/ML

injectable Prescription INJECTION AP Nov 25, 2019





4. NORVIUM BIOSCIENCE

Norvium Bioscience Llc has filed for 1 generic for Cladribine. Given below are the details of the strengths of this generic introduced by Norvium Bioscience.

Strength Dosage Form Availability Application Pathway TE code Launch Date
1MG/ML

injectable Discontinued INJECTION N/A Oct 6, 2011





Cladribine News

BioNxt progresses with patent applications for innovative drug delivery technology - from WebDisclosure

29 Oct, 2024

See More